1. Home
  2. COGT vs CNX Comparison

COGT vs CNX Comparison

Compare COGT & CNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cogent Biosciences Inc.

COGT

Cogent Biosciences Inc.

SELL

Current Price

$27.46

Market Cap

5.5B

Sector

Health Care

ML Signal

SELL

Logo CNX Resources Corporation

CNX

CNX Resources Corporation

SELL

Current Price

$36.17

Market Cap

5.3B

Sector

Energy

ML Signal

SELL

Company Overview

Basic Information
Metric
COGT
CNX
Founded
2014
1860
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Oil & Gas Production
Sector
Health Care
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
5.5B
5.3B
IPO Year
2018
1998

Fundamental Metrics

Financial Performance
Metric
COGT
CNX
Price
$27.46
$36.17
Analyst Decision
Strong Buy
Hold
Analyst Count
12
12
Target Price
★ $55.82
$38.33
AVG Volume (30 Days)
★ 2.0M
1.6M
Earning Date
11-05-2026
10-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 763.33
EPS
N/A
★ 4.70
Revenue
$7,871,000.00
★ $2,239,134,000.00
Revenue This Year
N/A
$14.50
Revenue Next Year
$5,819.52
N/A
P/E Ratio
★ N/A
$7.77
Revenue Growth
N/A
★ 76.76
52 Week Low
$27.74
$30.78
52 Week High
$43.73
$43.62

Technical Indicators

Market Signals
Indicator
COGT
CNX
Relative Strength Index (RSI) 37.79 50.75
Support Level N/A $35.12
Resistance Level $37.34 $37.01
Average True Range (ATR) 1.81 1.08
MACD -0.30 -0.13
Stochastic Oscillator 4.41 28.16

Price Performance

Historical Comparison
COGT
CNX

About COGT Cogent Biosciences Inc.

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

About CNX CNX Resources Corporation

CNX Resources Corp is an independent natural gas development, production, midstream and technology company centered in the Appalachian Basin. It is focused on unconventional shale formations, prominently the Marcellus Shale and Utica Shale, in Pennsylvania, Ohio and West Virginia. Additionally, the company operates and develops Coalbed Methane (CBM) properties in Virginia. the company has two reportable segments: Shale and Coalbed Methane. The majority of the company's revenue is derived from the Shale segment.

Share on Social Networks: